Business
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm® Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies to exp
About this update from Avita Medical, Inc.
[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDr4RdwXqFCjMdbUOz.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"text","content":"VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm® Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies to expand the reach and availability of PermeaDerm.","length":545,"tagName":"p"},{"type":"text","content":"Under the terms of the new Contract Manufacturing Agreement, effective as of March 17, 2025, AVITA Medical is to manufacture PermeaDerm at its state-of-the-art manufacturing facility in Ventura, California. This agreement ensures the continued availability of this innovative transparent biosynthetic wound matrix while optimizing AVITA Medical’s production capabilities to meet growing market demand. AVITA Medical will utilize its existing infrastructure to support the further commercialization of PermeaDerm in the U.S. while streamlining production, increasing scale, and optimizing manufacturing cost efficiencies to drive greater value.","length":643,"tagName":"p"},{"type":"text","content":"The Exclusive Distribution Agreement originally executed in January 2024 has been amended to align with the new manufacturing arrangement. This revised agreement modifies revenue-sharing terms, establishes performance-based milestones, and extends the contract term. Under these new terms, AVITA Medical will retain 60% of the average sales price from PermeaDerm sales while remitting 40% to Stedical after deducting manufacturing costs. Prior to the amendment, each party retained 50% of the average sales price from the sale of PermeaDerm.","length":54...